HbA1c-Informed Pattern Recognition for Diabetes Mellitus Classification and Hospital Readmission Risk Analysis

Abstract

Glycated hemoglobin (HbA1c) is an established indicator of longer-term glycaemic exposure, but hospital readmission risk in patients with diabetes depends on additional clinical and healthcare-utilization factors. This paper presents a reproducible pattern-recognition framework that incorporates HbA1c and structured clinical variables from the Diabetes 130-US Hospitals for Years 1999–2008 dataset. The resource contains 101,766 inpatient encounters across 130 U.S. hospitals and integrated delivery networks. The proposed analysis addresses missing values, categorical encoding, patient-level data leakage, class imbalance, and model calibration. We compare logistic regression, decision trees, random forests, support vector machines, and gradient-boosting classifiers. Because the supplied source paper does not contain reproducible experimental predictions or raw model outputs, no new accuracy or area-under-the-curve values are claimed. Instead, the study motivates a transparent model-validation protocol and uses published performance estimates strictly as contextual benchmarks. The framework is intended for research and clinician-supported risk stratification, not autonomous diagnosis.

Introduction

The study proposes a machine learning framework to predict 30-day hospital readmission among patients with diabetes, considering HbA1c status alongside demographic information, medical history, comorbidities, medication details, and previous healthcare utilization. HbA1c is an important indicator of average blood glucose levels over approximately two to three months, but its interpretation can be affected by conditions such as anemia, blood loss, and hemoglobin variants.

The research uses the Diabetes 130-US Hospitals dataset, available through the UCI Machine Learning Repository, which contains 101,766 hospital encounters from 130 US healthcare settings between 1999 and 2008. The study distinguishes two tasks: predicting early hospital readmission and classifying recorded HbA1c categories. These tasks are evaluated separately because they represent different clinical outcomes.

The proposed methodology includes data cleaning, missing-value handling, feature engineering, and patient-separated training and testing to prevent data leakage. Five machine learning models are considered: Logistic Regression, Decision Tree, Random Forest, Support Vector Machine (SVM), and Gradient Boosting such as XGBoost. Their performance will be evaluated using ROC-AUC, PR-AUC, precision, recall, F1-score, sensitivity, specificity, and calibration measures.

The framework also emphasizes class imbalance, fairness across patient subgroups, model interpretability, and reliable probability estimates. An ablation study comparing models with and without HbA1c information will help determine whether HbA1c adds predictive value beyond other clinical variables. The research further highlights the importance of distinguishing missing HbA1c measurements from normal or elevated results.

In conclusion, the study provides a systematic and clinically informed framework for developing reliable machine learning models for early hospital readmission prediction among patients with diabetes. However, it is a proposed research methodology rather than a completed model evaluation; no new trained-model results or independently verified performance scores are reported. The ultimate aim is to support better discharge planning, identify patients who may need additional follow-up, and improve continuity of diabetes care.

Conclusion

HbA1c-informed pattern recognition offers a plausible framework for organizing diabetes hospital records into clinically interpretable risk profiles. The UCI Diabetes 130-US Hospitals dataset provides a substantial historical foundation for comparing transparent baselines and nonlinear machine-learning methods, but it does not by itself establish a deployable predictor. A defensible analysis must separate A1c measurement from observed category, prevent repeated-patient leakage, quantify minority-class detection, assess probability calibration, and validate across patient groups. The present paper contributes a reproducible study design and evidence synthesis while explicitly reserving original performance claims for empirical execution. Its anticipated role is decision support for clinical review and discharge planning, never an autonomous substitute for professional judgment.

References

[1] American Diabetes Association Professional Practice Committee, “2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026,” Diabetes Care, vol. 49, suppl. 1, pp. S27–S49, 2026, doi: 10.2337/dc26-S002. [2] J. Clore, K. Cios, J. DeShazo, and B. Strack, “Diabetes 130-US Hospitals for Years 1999–2008,” UCI Machine Learning Repository, 2014, doi: 10.24432/C5230J. [3] B. Strack et al., “Impact of HbA1c measurement on hospital readmission rates: Analysis of 70,000 clinical database patient records,” BioMed Research International, vol. 2014, Art. no. 781670, 2014, doi: 10.1155/2014/781670. [4] S. M. Srinivasan, Y. F. Paat, P. Halls, R. Kalule, and T. E. Harvey, “Predicting re-admission to hospital for diabetes treatment: A machine learning solution,” International Journal of Computational Biology and Drug Design, vol. 13, nos. 5–6, pp. 539–554, 2020, doi: 10.1504/IJCBDD.2020.113823. [5] O. G. Emi-Johnson and K. J. Nkrumah, “Predicting 30-Day Hospital Readmission in Patients With Diabetes Using Machine Learning on Electronic Health Record Data,” Cureus, vol. 17, no. 4, Art. no. e82437, Apr. 2025, doi: 10.7759/cureus.82437. [6] S. S. Salim and A. A. Ibrahim, “A Machine Learning Approach for Predicting 30-Day Hospital Readmission in Patients with Diabetes,” Healthcare, vol. 14, no. 9, Art. no. 1185, Apr. 2026, doi: 10.3390/healthcare14091185. [7] American Diabetes Association Professional Practice Committee for Diabetes, “16. Diabetes Care in the Hospital: Standards of Care in Diabetes—2026,” Diabetes Care, vol. 49, suppl. 1, pp. S339–S355, 2026, doi: 10.2337/dc26-S016. [8] G. S. Collins et al., “TRIPOD+AI statement: Updated guidance for reporting clinical prediction models that use regression or machine learning methods,” BMJ, vol. 385, Art. no. e078378, 2024, doi: 10.1136/bmj-2023-078378. [9] K. G. M. Moons et al., “PROBAST+AI: An updated quality, risk of bias, and applicability assessment tool for prediction models using regression or artificial intelligence methods,” BMJ, vol. 388, Art. no. e082505, 2025, doi: 10.1136/bmj-2024-082505. [10] L. M. Stevens, B. J. Mortazavi, R. C. Deo, L. Curtis, and D. P. Kao, “Recommendations for reporting machine learning analyses in clinical research,” Circ. Cardiovasc. Qual. Outcomes, vol. 13, no. 10, Art. no. e006556, 2020, doi: 10.1161/CIRCOUTCOMES.120.006556. [11] T. Saito and M. Rehmsmeier, “The precision-recall plot is more informative than the ROC plot when evaluating binary classifiers on imbalanced datasets,” PLoS ONE, vol. 10, no. 3, Art. no. e0118432, 2015, doi: 10.1371/journal.pone.0118432. [12] B. Van Calster et al., “Calibration: The Achilles heel of predictive analytics,” BMC Med., vol. 17, Art. no. 230, 2019, doi: 10.1186/s12916-019-1466-7. [13] S. M. Lundberg and S.-I. Lee, “A unified approach to interpreting model predictions,” in Advances in Neural Information Processing Systems, vol. 30, 2017. [14] C. Rudin, “Stop explaining black box machine learning models for high stakes decisions and use interpretable models instead,” Nat. Mach. Intell., vol. 1, pp. 206–215, 2019, doi: 10.1038/s42256-019-0048-x. [15] M. Ghassemi, L. Oakden-Rayner, and A. L. Beam, “The false hope of current approaches to explainable artificial intelligence in health care,” Lancet Digit. Health, vol. 3, no. 11, pp. e745–e750, 2021, doi: 10.1016/S2589-7500(21)00208-9. [16] A. J. Vickers and E. B. Elkin, “Decision curve analysis: A novel method for evaluating prediction models,” Med. Decis. Making, vol. 26, no. 6, pp. 565–574, 2006, doi: 10.1177/0272989X06295361. [17] Z. Obermeyer, B. Powers, C. Vogeli, and S. Mullainathan, “Dissecting racial bias in an algorithm used to manage the health of populations,” Science, vol. 366, no. 6464, pp. 447–453, 2019, doi: 10.1126/science.aax2342. [18] X. Liu et al., “Reporting guidelines for clinical trial reports for interventions involving artificial intelligence: The CONSORT-AI extension,” Nat. Med., vol. 26, pp. 1364–1374, 2020, doi: 10.1038/s41591-020-1034-x.

Copyright

Copyright © 2026 Sarita B. Ghansawant, Abhijeet G. Dhepe, Dr. Mukta G. Dhopeshwarkar. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.